Genentech cancer med nabs Breakthrough status

Share this article:

Roche subsidiary Genentech scored a breakthrough-therapy designation for its experimental Phase-I immuno-oncology drug MPDL3280A. The anticipated patient population is comprised of previously treated metastatic urothelial bladder cancer patients who test positive for PD-L1, which stands for programmed death ligand-1. The test is being developed by parent company Roche.

Genentech said in a statement Saturday that results prompting the FDA's breakthrough label showed tumors shrank in 43% of patients.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.